Visby Management Reiterates Superior Offer to LCL Resources
Visby Urges Shareholders to Reject Tiger Gold Proposal
MEDELLIN, Colombia, June 2, 2025 /PRNewswire/ — Visby Management LLC ('Visby'), an international mine operator with operations in Colombia, would like to reiterate its superior, binding offer to acquire the Colombian assets of Los Cerros Limited (ASX: LCL) ('LCL') and is urging LCL shareholders to vote against the proposed transaction with Tiger Gold Corporation ('TGC') at the AGM on June 9, 2025. Visby also encourages shareholders to communicate their support for Visby's proposal at the upcoming LCL public webinar to be held on June 5, 2025.
Visby has submitted multiple binding offers to LCL to acquire the company's Colombian assets. In February 2025, Visby presented LCL with a superior offer and encouraged shareholders to vote against the latest TGC offer so that the company could consider it. Subsequently, 84% of shareholders at the February shareholder meeting voted against the TGC offer. Visby has since approached LCL with multiple offers superior to what TGC has offered but the LCL board has consistently refused to engage in discussions or allow shareholders to evaluate Visby's superior offers. Despite a clear message from shareholders in February, the LCL board is again recommending shareholders vote in favor of TGC at the upcoming June 9, 2025 AGM.
In hopes of getting support from understandably disgruntled shareholders, LCL scheduled a webinar for June 5, 2025 to presumably persuade shareholders on the TGC sale option. Upon learning of the webinar, Visby requested the opportunity to present its offer to shareholders in this same forum. The LCL board refused Visby's offer.
So that shareholders may make the most informed vote at the upcoming AGM, Visby would like to reiterate the following points:
The proposed TGC transaction is an option with only AUD $1m upfront, as LCL has stated on multiple occasions, and there is no guarantee TGC will deliver on the second payment due in eight months.
Despite an intentional lack of clarity from LCL's board, the TGC option does require shareholder approval.
The TGC agreement may be binding, but only as long as shareholders approve it.
With these points in mind, Visby would like to reiterate its binding AUD $15 million offer which includes:
Upfront payment of AUD $7.5 million (proof of funds available)
AUD $7.5 million on first gold pour
1% NSR
Visby is an experienced mine operator which has built successful open pit gold mines in Colombia. Any shareholder who would like to discuss Visby's credentials is welcome to contact us at the email below. Given that approval of the TGC option requires shareholder approval, Visby encourages shareholders to vote in their best interest at the upcoming AGM and reject the TCG proposal so that Visby's superior option is considered.
ContactPresidentRoy Ostrom IIIVisby Managementinfo@visbymgmt.com
Photo: https://mma.prnewswire.com/media/2700791/Visby.jpg
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
6 hours ago
- Malaysian Reserve
Neurizon Enters into Global License with Elanco to Accelerate Commercialisation of NUZ-001
Highlights: Neurizon® Therapeutics and Elanco Animal Health enter into an exclusive global licensing agreement Provides worldwide rights for Neurizon to utilise Elanco's intellectual property, providing exclusive access to an extensive package of non-clinical studies and manufacturing data and outlines key terms for a future supply agreement for GMP-compliant Monepantel Provides a clear pathway for accelerated global commercialisation of NUZ-001[1] and significantly de-risks future global regulatory approval processes The license agreement represents the first step in formalising Neurizon's relationship with Elanco, with the next step focused on finalising a supply agreement expected H2 CY 2025 MELBOURNE, Australia, July 2, 2025 /PRNewswire/ — Neurizon Therapeutics Limited (ASX: NUZ & NUZOA) ('Neurizon' or 'the Company'), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce it has executed an exclusive global license agreement with Elanco Animal Health Incorporated (Elanco; NYSE: ELAN) and affiliates for Monepantel, the active pharmaceutical ingredient in NUZ-001, Neurizon's lead investigational therapy in development for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases in humans. This license agreement represents a critical inflection point for Neurizon, further strengthening the Company's strategic outlook for the development, manufacturing and potential future commercialisation of NUZ-001. It also significantly supports the Company's regulatory foundations, providing ongoing access to critical animal safety data and manufacturing data, key pillars required to support future clinical trials, potential regulatory approvals and global market entry. Dr. Michael Thurn, Managing Director and Chief Executive Officer, commented: 'This license agreement with Elanco marks a watershed moment in Neurizon's journey to become a leader in the accelerated development of treatments for neurodegenerative diseases. This strategic milestone provides exclusive access to a comprehensive package of non-clinical studies and manufacturing data, dramatically reducing near-term development costs and accelerating development timelines. All of this is in exchange for a nominal up-front payment, small back-ended regulatory approval and commercial sale milestones and single-digit royalty payments on future global net sales. Neurizon is now well-positioned to accelerate the path to market and advance new treatment options for people affected by devastating neurodegenerative diseases.' Mr. Sergio Duchini, Non-Executive Chairman, commented: 'On behalf of the Board, I am pleased to endorse this landmark agreement with Elanco, which represents a strategically significant step forward for Neurizon. This agreement not only strengthens our clinical and regulatory position but also reflects our strong commitment to accelerating the development of meaningful therapies for people living with neurodegenerative diseases. We are also very happy to be making this important step in formalising our relationship with Elanco and look forward to building on this foundation as we progress towards finalising a supply agreement later this year.' Key Terms of the Licensing Agreement: Exclusive Global Rights: Neurizon is granted exclusive global rights to Elanco's data package and related intellectual property for monepantel to develop and commercialise NUZ-001 and its related compounds for the treatment, palliation, prevention, or cure of neurodegenerative diseases in humans. Upfront Payment: A nominal upfront licensing fee is payable to Elanco upon execution of the agreement[2]. Milestone Payments: Total Development milestone payments for the initial and subsequent licensed products, indications, or presentations of US$9.75 million and US$5.2 million, respectively. Elanco will also be eligible for milestone payments of up to US $65 million based on sales milestones[3]. Royalties: Elanco will receive tiered single-digit royalties on global net sales of licensed products. Supply: The agreement outlines certain key terms, including duration and price, for the conclusion of a Supply Agreement. Supply Agreement Neurizon and Elanco remain focused on finalising a supply agreement, with a follow-up announcement anticipated in H2 CY 2025. This next phase of the collaboration is expected to provide Neurizon with long-term, scalable source of GMP-compliant monepantel to support ongoing clinical development, regulatory submissions, and future global commercialisation of NUZ-001. -ENDS- This announcement has been authorized for release by the Board of Neurizon Therapeutics Limited. About Neurizon Therapeutics Limited Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon's strategy is to accelerate access to effective ALS treatments for patients while exploring NUZ-001's potential for broader neurodegenerative applications. Through international collaborations and rigorous clinical programs, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders. Neurizon® is a registered trademark of Neurizon Therapeutics Limited [1] NUZ-001 is Neurizon Therapeutics formulation of monepantel for use in neurodegeneration applications. [2] The amount is not material to Neurizon's current cash position [3] If triggered, the sales milestone payments will not fall due until six months after the first commercial sale. The remaining regulatory and commercial milestone payments will become due 30 days after the relevant milestone is met.
Malaysian Reserve
5 days ago
- Malaysian Reserve
Ecopetrol Extends Temporary 50% Fee Reduction Agreement for ADR Conversion in the United States
BOGOTA, Colombia, June 27, 2025 /PRNewswire/ — Ecopetrol announces that, following discussions with its ADR (American Depositary Receipts) program depositary bank, JPMorgan Chase Bank N.A., it has successfully extended the agreement to reduce by 50% the conversion fees for the issuance and cancellation of ADRs in the United States. This measure, originally announced on January 15, 2025, was initially set to remain in effect until July 10, 2025. With the extension, it will now remain valid through December 31, 2025. Given the positive reception of this initiative in the market, Ecopetrol has worked to ensure its continuation in order to support the interests of its investors. For more information, please refer to the following link —————————————– Ecopetrol is the largest company in Colombia and one of the main integrated energy companies in the American continent, with more than 18,000 employees. In Colombia, it is responsible for more than 60% of the hydrocarbon production of most transportation, logistics, and hydrocarbon refining systems, and it holds leading positions in the petrochemicals and gas distribution segments. With the acquisition of 51.4% of ISA's shares, the company participates in energy transmission, the management of real-time systems (XM), and the Barranquilla – Cartagena coastal highway concession. At the international level, Ecopetrol has a stake in strategic basins in the American continent, with Drilling and Exploration operations in the United States (Permian basin and the Gulf of Mexico), Brazil, and Mexico, and, through ISA and its subsidiaries, Ecopetrol holds leading positions in the power transmission business in Brazil, Chile, Peru, and Bolivia, road concessions in Chile, and the telecommunications sector. This press release contains business prospect statements, operating and financial result estimates, and statements related to Ecopetrol's growth prospects. These are all projections and, as such, they are based solely on the expectations of the managers regarding the future of the company and their continued access to capital to finance the company's business plan. The realization of said estimates in the future depends on the behavior of market conditions, regulations, competition, and the performance of the Colombian economy and the industry, among other factors, and are consequently subject to change without prior notice. This release contains statements that may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. All forward-looking statements, whether made in this release or in future filings or press releases, or orally, address matters that involve risks and uncertainties, including in respect of the Company's prospects for growth and its ongoing access to capital to fund the Company's business plan, among others. Consequently, changes in the following factors, among others, could cause actual results to differ materially from those included in the forward-looking statements: market prices of oil & gas, our exploration, and production activities, market conditions, applicable regulations, the exchange rate, the Company's competitiveness and the performance of Colombia's economy and industry, to mention a few. We do not intend and do not assume any obligation to update these forward-looking statements. For more information, please contact: Head of Corporate Communications Angela Maria De la Pava Londoño Email: investors@ Head of Press Juan Pablo Pacavita Email:
New Straits Times
16-06-2025
- New Straits Times
Australia, New Zealand dollars vulnerable as Israel-Iran conflict escalates
SYDNEY: The Australian and New Zealand dollars remained vulnerable to declines on Monday as the conflict between Israel and Iran showed no sign of cooling and oil prices climbed anew, although the sell-off in global stocks did steady slightly. The Aussie dropped 0.3 per cent to US$0.6470, having fallen 0.7 per cent on Friday to as low as US$0.6457. It has support at the 200-day moving average of US$0.6429, while resistance is stiff at US$0.6550. The New Zealand dollar was flat at US$0.6008, after diving 0.9 per cent on Friday to as low as US$0.5996. It has support at 60 US cents. On Monday, Wall Street futures climbed slightly while currency markets were mostly calm as investors assessed the latest developments in the Middle East. Iranian missiles struck Israel's Tel Aviv and the port city of Haifa on Monday, destroying homes and fuelling concerns that the situation could escalate into a broader regional conflict. "The main influence on AUD/USD this week is likely to be the conflict in the Middle East and the FOMC meeting," said Joseph Capurso, head of international economics at the Commonwealth Bank of Australia, referring to the US Federal Open Market Committee meeting starting on Tuesday. "AUD/USD could fall nearer support at 0.6307 if the conflict escalates significantly." Strategists from Deutsche Bank noted that the performance of the Australian dollar has a negative correlation with oil prices, even though Australia has become an energy exporter in recent years. Australia will publish monthly jobs figures on Thursday, where expectations are for a gain of 25,000 jobs in May and a steady jobless rate of 4.1 per cent. The labour market has been surprisingly resilient, and another strong print could challenge market pricing for a rate cut next month, which is now priced at 75 per cent. New Zealand will release its first-quarter gross domestic product figures on Thursday, where forecasts are for a solid quarterly growth rate of 0.7 per cent as the economy emerges from a policy-induced downturn. "Our 0.7 per cent growth forecast is an upgrade from our previous estimate of 0.4 per cent... The signs of strength in the sectoral data were something of a surprise for us," said Michael Gordon, senior economist at Westpac. Swaps imply there might be just one rate cut left in the current easing cycle from the Reserve Bank of New Zealand, which is more than fully priced in by November.
